DIAGNOSTIC ACCURACY OF ENDOFASTER COMPARED TO HISTOLOGY FOR CHRONIC ATROPHIC GASTRITIS USING NARROW BAND IMAGING (NBI) TARGETED BIOPSIES: A REAL-TIME PROSPECTIVE STUDY

2019 ◽  
Author(s):  
G Esposito ◽  
M Cazzato ◽  
G Galli ◽  
L Conti ◽  
E Lahner ◽  
...  
2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
M. Cazzato ◽  
G. Esposito ◽  
G. Galli ◽  
E. Pilozzi ◽  
E. Lahner ◽  
...  

Background. EndoFaster® analyzes gastric juice in real time during gastroscopy allowing the detection of hypo-achlorhydric conditions, like corpus atrophic gastritis. Narrow-band imaging (NBI) endoscopy allows to accurately detect and perform target biopsies in areas of intestinal metaplasia, a histological change often associated to corpus atrophic gastritis. Aims. To compare the diagnostic accuracy of EndoFaster® with histological evaluation for corpus atrophic gastritis through high-resolution (HR) NBI targeted biopsies. Methods. Prospective study on consecutive adult patients undergoing gastroscopy between April and November 2018. Patients in therapy with proton pump inhibitors, previous gastric surgery, and/or known gastric neoplasia were excluded. At the beginning of gastroscopy, gastric juice was aspirated and analyzed by EndoFaster® in 15 seconds. Endoscopists were blinded to the report of EndoFaster®. Evaluation of gastric mucosa in HR-white light was firstly performed, then with HR-NBI allowing to perform targeted biopsies on areas suspected for intestinal metaplasia; otherwise, biopsies were performed according to the updated Sydney System protocol and sent for histopathological evaluation. Results. Overall, 124 patients were included [64% F; 56 (18-85) years]. Corpus atrophic gastritis was present in 41.9% of patients. EndoFaster® showed an accuracy for corpus atrophic gastritis diagnosis, compared to histopathological evaluation as gold standard, of 87.1% and a sensitivity, specificity, PPV, and NPV of 78.8%, 93.1%, 89.1%, and 85.9%, respectively. pH showed a positive correlation with the severity score of atrophy ( r = 0.67 , 95% CI: 0.73-0.81, and p < 0.0001 ). EndoFaster® allowed to diagnose corpus atrophic gastritis in 3.7% of patients negative to NBI (corpus atrophic gastritis without intestinal metaplasia). Conclusion. EndoFaster® seems a promising tool to diagnose corpus atrophic gastritis. The evaluation of hypo-achlorhydria during gastroscopy can address bioptic sampling in corpus atrophic gastritis patients without intestinal metaplasia.


2020 ◽  
Author(s):  
Alberto Deganello ◽  
Alberto Paderno ◽  
Riccardo Morello ◽  
Milena Fior ◽  
Giulia Berretti ◽  
...  

Endoscopy ◽  
2016 ◽  
Vol 48 (08) ◽  
pp. 723-730 ◽  
Author(s):  
Pedro Pimentel-Nunes ◽  
Diogo Libânio ◽  
Jorge Lage ◽  
Diogo Abrantes ◽  
Miguel Coimbra ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document